Differentiating Alzheimer's Aβ Isoforms Coaggregated in Cerebrospinal Fluid via Single-Particle Imaging

Lily Henry1, Shayon Bhattacharya2, Talia Bergaglio1

  • 1Transport at Nanoscale Interfaces Laboratory, Swiss Federal Laboratories for Materials Science and Technology, Dübendorf CH-8600, Switzerland.

ACS Chemical Neuroscience
|January 14, 2026
PubMed

Insights

Alzheimer

Area of Science:

  • Neuroscience
  • Biochemistry
  • Biophysics

Background:

  • Amyloid polymorphism correlates with Alzheimer's disease (AD) stages.
  • Amyloid-beta (Aβ) peptides, specifically Aβ-40 and Aβ-42, are central to AD pathology.
  • Cerebrospinal fluid (CSF) contains Aβ peptides whose aggregation patterns may indicate disease progression.

Purpose of the Study:

  • To differentiate and characterize the morphology of Aβ-40 and Aβ-42 peptides in CSF.
  • To investigate the inhibitory effect of Aβ-40 on Aβ-42 aggregation at a single-particle level.
  • To explore the role of the CSF ionic environment in modulating Aβ coaggregation.

Main Methods:

  • Utilized fluorescence-based super-resolution microscopy and atomic force microscopy (AFM) for detailed Aβ morphology studies.
  • Employed molecular dynamics simulations to understand the mechanisms of Aβ coaggregation.
  • Developed an isoform-specific imaging method for distinguishing Aβ aggregate types in patient CSF.

Main Results:

  • Resolved the inhibitory effect of Aβ-40 on Aβ-42 aggregation, with Aβ-40 oligomers observed on Aβ-42 fibril backbones.
  • Identified calcium ions in CSF as key mediators, forming bridges between Aβ-40 and Aβ-42 that stabilize fibrils and reduce elongation.
  • Quantified nanoscopic differences in Aβ aggregate sizes (oligomers to fibrils) from AFM data in AD patient CSF.

Conclusions:

  • The developed protein characterization method can fingerprint Aβ aggregates in CSF, irrespective of size or shape.
  • This approach enables the distinction of Aβ-40 and Aβ-42 aggregates, offering insights into AD.
  • Potential clinical application for monitoring Alzheimer's disease progression and related pathologies through CSF Aβ analysis.